Details of the Drug

General Information of Drug (ID: DM353WG)

Drug Name
TAP311
Indication
Disease Entry ICD 11 Status REF
Dyslipidemia 5C80-5C81 Phase 1 [1]
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C34H40F6N6O4
Canonical SMILES
CCC1CC(CC(N1C(=O)OC2CCC(CC2)C(=O)O)CC)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)C5=CN(N=C5)C
InChI
InChI=1S/C34H40F6N6O4/c1-4-26-13-28(14-27(5-2)46(26)32(49)50-29-8-6-21(7-9-29)30(47)48)45(31-41-15-22(16-42-31)23-17-43-44(3)19-23)18-20-10-24(33(35,36)37)12-25(11-20)34(38,39)40/h10-12,15-17,19,21,26-29H,4-9,13-14,18H2,1-3H3,(H,47,48)/t21?,26-,27+,28?,29?
InChIKey
KSPXRTYMEVDHAB-LTZKBQIGSA-N
Cross-matching ID
PubChem CID
57686716
TTD ID
D08VBV
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

References

1 ClinicalTrials.gov (NCT01487460) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients. U.S. National Institutes of Health.